GSK (LON:GSK - Get Free Report)'s stock had its "hold" rating reissued by analysts at Deutsche Bank Aktiengesellschaft in a research note issued to investors on Monday, Marketbeat Ratings reports. They currently have a GBX 1,450 ($19.70) price target on the stock. Deutsche Bank Aktiengesellschaft's price target would suggest a potential upside of 4.28% from the company's previous close.
A number of other equities research analysts also recently issued reports on the company. Berenberg Bank restated a "hold" rating and set a GBX 1,600 ($21.74) price target on shares of GSK in a research note on Friday, July 18th. Shore Capital restated a "buy" rating and set a GBX 2,000 ($27.17) price objective on shares of GSK in a research report on Friday, July 18th. Finally, JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of GSK in a research note on Friday, July 18th.
Check Out Our Latest Report on GSK
GSK Stock Up 1.4%
GSK traded up GBX 19 ($0.26) during midday trading on Monday, reaching GBX 1,390.50 ($18.89). The company's stock had a trading volume of 8,375,221 shares, compared to its average volume of 13,605,646. The firm has a market capitalization of £56.42 billion, a price-to-earnings ratio of 22.46, a PEG ratio of 1.24 and a beta of 0.31. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. GSK has a 1 year low of GBX 1,242.50 ($16.88) and a 1 year high of GBX 1,678.68 ($22.81). The stock's 50-day moving average is GBX 1,434.41 and its 200-day moving average is GBX 1,422.29.
GSK (LON:GSK - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.61) earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, research analysts expect that GSK will post 175.980975 EPS for the current year.
Insiders Place Their Bets
In other news, insider Wendy Becker purchased 545 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was purchased at an average cost of GBX 1,435 ($19.50) per share, with a total value of £7,820.75 ($10,626.02). Also, insider Emma Walmsley sold 5,473 shares of GSK stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of GBX 1,449 ($19.69), for a total transaction of £79,303.77 ($107,749.69). Insiders acquired 1,905 shares of company stock valued at $2,732,835 in the last three months. Corporate insiders own 1.61% of the company's stock.
GSK Company Profile
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Articles
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.